
TY  - JOUR
C7  - e27057
TI  - 2018 ASPHO ABSTRACTS
JO  - Pediatric Blood & Cancer
JA  - Pediatr Blood Cancer
VL  - 65
IS  - S1
SN  - 1545-5009
UR  - https://doi.org/10.1002/pbc.27057
DO  - doi:10.1002/pbc.27057
SP  - e27057
PY  - 2018
ER  - 

TY  - JOUR
TI  - SARS POSTERS 2010
JO  - BJS (British Journal of Surgery)
JA  - Br J Surg
VL  - 97
IS  - S6
SN  - 0007-1323
UR  - https://doi.org/10.1002/bjs.7352
DO  - doi:10.1002/bjs.7352
SP  - 39
EP  - 53
PY  - 2010
ER  - 

TY  - JOUR
TI  - American College of Clinical Pharmacy: 2004 ANNUAL MEETING October, 24–27, 2004 Dallas, TX
JO  - Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
VL  - 24
IS  - 10
SN  - 0277-0008
UR  - https://doi.org/10.1592/phco.24.14.1419.43157
DO  - doi:10.1592/phco.24.14.1419.43157
SP  - 1419
EP  - 1489
PY  - 2004
ER  - 

TY  - JOUR
AU  - Enden, Tone
AU  - Garratt, Andrew Malcolm
AU  - Kløw, Nils-Einar
AU  - Sandset, Per Morten
TI  - Assessing burden of illness following acute deep vein thrombosis: data quality, reliability and validity of the Norwegian version of VEINES-QOL/Sym, a disease-specific questionnaire
JO  - Scandinavian Journal of Caring Sciences
VL  - 23
IS  - 2
SN  - 0283-9318
UR  - https://doi.org/10.1111/j.1471-6712.2008.00618.x
DO  - doi:10.1111/j.1471-6712.2008.00618.x
SP  - 369
EP  - 374
KW  - deep vein thrombosis
KW  - EQ-5D
KW  - postthrombotic syndrome
KW  - quality of life
KW  - reliability
KW  - validity
PY  - 2009
AB  - The data quality, reliability and validity of the Norwegian version of VEINES-QOL/Sym were assessed in 74 patients with deep vein thrombosis (DVT). This patient-reported questionnaire produces two scale scores of venous disease-specific quality of life and venous symptoms. Items had low levels of missing data. Item-total correlations ranged from 0.41 to 0.78 with the exception of 0.29 for the symptom item ?night cramps?. Internal consistency was supported by Cronbach?s alpha of 0.88 and 0.94 for VEINES-Sym and VEINES-QOL, respectively. Test?retest reliability assessed for 40 patients gave intraclass correlation coefficients of 0.83 and 0.88 for VEINES-Sym and VEINES-QOL, respectively. Assessment of correlation between the two scales and other clinical measures supports the construct validity of the scales. The results indicate acceptable internal consistency, test?retest reliability and validity of the Norwegian version of the VEINES-QOL/Sym questionnaire in patients with DVT. The results follow those of previous studies, and support the use of VEINES-QOL/Sym in the evaluation of patient outcomes and burden of illness in clinical studies of venous thrombosis.
ER  - 

TY  - JOUR
TI  - 2019 ACCP Annual Meeting
JO  - JACCP:  JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY
JA  - J Am Coll Clin Pharm
VL  - 3
IS  - 1
UR  - https://doi.org/10.1002/jac5.1204
DO  - doi:10.1002/jac5.1204
SP  - 145
EP  - 391
PY  - 2020
ER  - 

TY  - JOUR
TI  - Publication Only
JO  - Journal of Thrombosis and Haemostasis
VL  - 9
IS  - s2
SN  - 1538-7933
UR  - https://doi.org/10.1111/j.1538-7836.2011.04380_6.x
DO  - doi:10.1111/j.1538-7836.2011.04380_6.x
SP  - 963
EP  - 970
PY  - 2011
ER  - 

TY  - JOUR
TI  - Abstract
JO  - Journal of Thrombosis and Haemostasis
JA  - Journal of Thrombosis and Haemostasis
VL  - 5
IS  - S2
SN  - 1538-7933
UR  - https://doi.org/10.1111/j.1538-7836.2007.tb00029.x
DO  - doi:10.1111/j.1538-7836.2007.tb00029.x
SP  - P-T-401
EP  - P-T-700
PY  - 2007
ER  - 

TY  - JOUR
TI  - E-Posters, EP1
JO  - BJOG: An International Journal of Obstetrics & Gynaecology
JA  - BJOG
VL  - 120
IS  - s1
SN  - 1470-0328
UR  - https://doi.org/10.1111/1471-0528.12293
DO  - doi:10.1111/1471-0528.12293
SP  - 19
EP  - 184
PY  - 2013
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Australasian Journal on Ageing
JA  - Australas J Ageing
VL  - 36
IS  - S2
SN  - 1440-6381
UR  - https://doi.org/10.1111/ajag.12419
DO  - doi:10.1111/ajag.12419
SP  - 19
EP  - 68
PY  - 2017
ER  - 

TY  - JOUR
TI  - Poster Presentation Abstracts
JO  - International Journal of Laboratory Hematology
JA  - Int. Jnl. Lab. Hem.
VL  - 36
IS  - s1
SN  - 1751-5521
UR  - https://doi.org/10.1111/ijlh.12266
DO  - doi:10.1111/ijlh.12266
SP  - 30
EP  - 131
PY  - 2014
ER  - 

TY  - JOUR
TI  - Oral papers
JO  - Journal of Thrombosis and Haemostasis
VL  - 8
IS  - s1
SN  - 1538-7933
UR  - https://doi.org/10.1111/j.1538-7836.2010.03959.x
DO  - doi:10.1111/j.1538-7836.2010.03959.x
SP  - 1
EP  - 44
PY  - 2010
ER  - 

TY  - JOUR
TI  - Short papers
JO  - BJS (British Journal of Surgery)
JA  - Br J Surg
VL  - 102
IS  - s1
SN  - 0007-1323
UR  - https://doi.org/10.1002/bjs.9729
DO  - doi:10.1002/bjs.9729
SP  - 9
EP  - 118
PY  - 2015
ER  - 

TY  - JOUR
TI  - Paper Abstract
JO  - Journal of the American Geriatrics Society
JA  - J Am Geriatr Soc
VL  - 66
IS  - S2
SN  - 0002-8614
UR  - https://doi.org/10.1111/jgs.15376
DO  - doi:10.1111/jgs.15376
SP  - S1
EP  - S369
PY  - 2018
ER  - 

TY  - JOUR
TI  - SARS abstracts
JO  - BJS (British Journal of Surgery)
JA  - Br J Surg
VL  - 102
IS  - s5
SN  - 0007-1323
UR  - https://doi.org/10.1002/bjs.9822
DO  - doi:10.1002/bjs.9822
SP  - 3
EP  - 52
PY  - 2015
ER  - 

TY  - JOUR
AU  - Malloy, Jaret
AU  - Zhuang, Dongliang
AU  - Kim, Terri
AU  - Inskeep, Phil
AU  - Kim, Dennis
AU  - Taylor, Kristin
TI  - Single and multiple dose evaluation of a novel MetAP2 inhibitor: Results of a randomized, double-blind, placebo-controlled clinical trial
JO  - Diabetes, Obesity and Metabolism
JA  - Diabetes Obes Metab
VL  - 20
IS  - 8
SN  - 1462-8902
UR  - https://doi.org/10.1111/dom.13305
DO  - doi:10.1111/dom.13305
SP  - 1878
EP  - 1884
KW  - antidiabetic drug
KW  - antiobesity drug
KW  - appetite control
KW  - lipid-lowering therapy
KW  - pharmacodynamics
KW  - pharmacokinetics
PY  - 2018
AB  - Aims Methionine aminopeptidase 2 (MetAP2) inhibition has been shown to result in significant weight loss and improved glucose control. This Phase 1 clinical trial assessed the safety and tolerability, pharmacokinetics and preliminary efficacy of a novel MetAP2 inhibitor, ZGN-1061. Methods This clinical trial included a single ascending dose (SAD) phase in healthy subjects (BMI, 23 to <30?kg/m2) and a multiple ascending dose (MAD) phase in otherwise healthy subjects (BMI, 27 to 40?kg/m2). SAD phase doses, administered subcutaneously (SC), were 0.2, 0.6, 1.2, 2.4, 3.6 and 4.8?mg and the MAD phase evaluated doses of 0.2, 0.6 and 1.8?mg twice weekly SC for 4?weeks. Results The SAD phase included 39 subjects (ZGN-1061, N?=?28; placebo, N?=?11); 90% were male and BMI was 26.4?kg/m2. ZGN-1061 was well tolerated across all doses, with the most frequent adverse events being mild headache and procedural-related irritation. There were no severe or serious adverse events. All doses of ZGN-1061 were rapidly absorbed and cleared, resulting in short duration of exposure that is anticipated to minimize potential off-drug target risks. The MAD phase included 29 subjects (ZGN-1061, N?=?22; placebo, N?=?7); 76% were male and BMI was 33.5?kg/m2. Safety observations were consistent with SAD findings. Efficacy measures in the MAD phase indicated trends for weight change (?1.5?kg total ZGN-1061 vs ?0.2?kg placebo) and other biomarker changes. Conclusions ZGN-1061 was well tolerated with no safety signals in all doses tested. In addition, the desired pharmacokinetic profile and preliminary efficacy observations with ZGN-1061 support evaluation in larger and longer clinical trials.
ER  - 

TY  - JOUR
AU  - Platt, Richard
AU  - Carnahan, Ryan
TI  - The U.S. Food and Drug Administration's Mini-Sentinel Program
JO  - Pharmacoepidemiology and Drug Safety
JA  - Pharmacoepidemiol Drug Saf
VL  - 21
IS  - S1
SN  - 1053-8569
UR  - https://doi.org/10.1002/pds.3230
DO  - doi:10.1002/pds.3230
SP  - 1
EP  - 303
PY  - 2012
AB  - No abstract is available for this article.
ER  - 

TY  - JOUR
TI  - Posters
JO  - Colorectal Disease
VL  - 13
IS  - s5
SN  - 1462-8910
UR  - https://doi.org/10.1111/j.1463-1318.2011.02656.x
DO  - doi:10.1111/j.1463-1318.2011.02656.x
SP  - 41
EP  - 88
PY  - 2011
ER  - 

TY  - JOUR
TI  - Research, Innovations, Clinical Vignettes Competition, Hospital Medicine 2011, May 10–13, 2011
JO  - Journal of Hospital Medicine
JA  - J. Hosp. Med.
VL  - 6
IS  - S2
SN  - 1553-5592
UR  - https://doi.org/10.1002/jhm.920
DO  - doi:10.1002/jhm.920
SP  - S1
EP  - S282
PY  - 2011
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Transplant International
JA  - Transpl Int
VL  - 29
IS  - S5
SN  - 0934-0874
UR  - https://doi.org/10.1111/tri.12867
DO  - doi:10.1111/tri.12867
SP  - 5
EP  - 16
PY  - 2016
ER  - 

TY  - JOUR
TI  - Free Paper Abstracts
JO  - Anaesthesia
JA  - Anaesthesia
VL  - 69
IS  - s4
SN  - 0003-2409
UR  - https://doi.org/10.1111/anae.12866
DO  - doi:10.1111/anae.12866
SP  - 11
EP  - 88
PY  - 2014
ER  - 
